Literature DB >> 35947346

Basal Cell Adenoma and Basal Cell Adenocarcinoma: a 50-year Experience From a Single Institution.

Miguel Rito1,2, Susana Esteves3, Isabel Fonseca4,5.   

Abstract

BACKGROUND: Basal cell adenoma (BCA) and adenocarcinoma (BCAd) are two of the least frequent salivary gland tumors. We describe the largest series of these neoplasms, spanning over a period of 50 years (1970-2020), diagnosed and treated in a single Institution.
METHODS: Sixty-eight cases were identified. Clinical and pathological data were collected and correlated with outcome.
RESULTS: Forty-one BCA and 27 BCAd were identified. BCA cases had almost pristine prognosis, with only a relapse in a tumor inadequately excised. Ten patients with BCAd developed metastases, and 14 died from the disease. The 2-year and 5-year survival was of 76% and 42%.
CONCLUSIONS: The importance of adequate excision is reinforced in BCA, with no recurrences occurring when margins were negative. Contrary to previous reports, BCAd was not associated with a good prognosis. A better understanding of the genetics of these neoplasms may identify therapeutic options when dealing with inoperable or metastatic disease.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Basal cell adenocarcinoma; Basal cell adenoma; Carcinoma ex pleomorphic adenoma; Head and neck neoplasms; Otorhinolaryngologic neoplasms; Salivary gland

Year:  2022        PMID: 35947346     DOI: 10.1007/s12105-022-01484-z

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  4 in total

1.  Frequent and differential mutations of the CYLD gene in basal cell salivary neoplasms: linkage to tumor development and progression.

Authors:  Miguel Rito; Yoshitsugu Mitani; Diana Bell; Fernanda Viviane Mariano; Salman T Almalki; Kristen B Pytynia; Isabel Fonseca; Adel K El-Naggar
Journal:  Mod Pathol       Date:  2018-02-20       Impact factor: 7.842

2.  Management of Salivary Gland Malignancy: ASCO Guideline.

Authors:  Jessica L Geiger; Nofisat Ismaila; Beth Beadle; Jimmy J Caudell; Nicole Chau; Daniel Deschler; Christine Glastonbury; Marnie Kaufman; Eric Lamarre; Harold Y Lau; Lisa Licitra; Michael G Moore; Cristina Rodriguez; Anna Roshal; Raja Seethala; Paul Swiecicki; Patrick Ha
Journal:  J Clin Oncol       Date:  2021-04-26       Impact factor: 44.544

3.  Carcinoma ex-pleomorphic adenoma of the salivary glands has a high risk of progression when the tumor invades more than 2.5 mm beyond the capsule of the residual pleomorphic adenoma.

Authors:  Miguel Rito; Isabel Fonseca
Journal:  Virchows Arch       Date:  2015-12-05       Impact factor: 4.064

Review 4.  Basal cell adenocarcinoma of minor salivary and seromucous glands of the head and neck region.

Authors:  I Fonseca; J Soares
Journal:  Semin Diagn Pathol       Date:  1996-05       Impact factor: 3.464

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.